Thromboxane receptor blockade reduces renal injury in murine lupus nephritis

Robert F. Spurney; Pang Yen Fan; Phillip Ruiz; Fred Sanfilippo; David S. Pisetsky; Thomas M. Coffman

Thromboxane receptor blockade reduces renal injury in murine lupus nephritis

Robert F. Spurney, Pang Yen Fan, Phillip Ruiz, Fred Sanfilippo, David S. Pisetsky, Thomas M. Coffman

Research output: Contribution to journal › Article › peer-review

Abstract

To investigate the role of thromboxane A₂ (TxA₂) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB₂) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.

Original language	English (US)
Pages (from-to)	973-982
Number of pages	10
Journal	Kidney International
Volume	41
Issue number	4
State	Published - Apr 1992
Externally published	Yes

ASJC Scopus subject areas

Nephrology

Fingerprint Dive into the research topics of 'Thromboxane receptor blockade reduces renal injury in murine lupus nephritis'. Together they form a unique fingerprint.

Cite this

@article{f05a4f2652454618aaa7c7a8b252e657,

title = "Thromboxane receptor blockade reduces renal injury in murine lupus nephritis",

abstract = "To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.",

author = "Spurney, {Robert F.} and Fan, {Pang Yen} and Phillip Ruiz and Fred Sanfilippo and Pisetsky, {David S.} and Coffman, {Thomas M.}",

year = "1992",

month = apr,

language = "English (US)",

volume = "41",

pages = "973--982",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Thromboxane receptor blockade reduces renal injury in murine lupus nephritis

AU - Spurney, Robert F.

AU - Fan, Pang Yen

AU - Ruiz, Phillip

AU - Sanfilippo, Fred

AU - Pisetsky, David S.

AU - Coffman, Thomas M.

PY - 1992/4

Y1 - 1992/4

N2 - To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.

AB - To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.

UR - http://www.scopus.com/inward/record.url?scp=0026536096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026536096&partnerID=8YFLogxK

M3 - Article

C2 - 1387435

AN - SCOPUS:0026536096

VL - 41

SP - 973

EP - 982

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -